Epigenetic Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemias

E-ISSN： 1875-533x|15|13|1274-1287

ISSN： 0929-8673

Source： Current Medicinal Chemistry, Vol.15, Iss.13, 2008-06, pp. : 1274-1287

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia

Current Cancer Drug Targets, Vol. 11, Iss. 7, 2011-09 ,pp. : 837-848

Bentham Science Publishers

Access to resources Recommend Favorite

Azacitidine: A Review of its Use in the Management of Myelodysplastic Syndromes/Acute Myeloid Leukaemia

By Keating Gillian M.

Drugs, Vol. 72, Iss. 8, 2012-05 ,pp. : 1111-1136

Adis International

Access to resources Recommend Favorite

Lenalidomide for Treatment of Myelodysplastic Syndromes

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3198-3203

Bentham Science Publishers

Access to resources Recommend Favorite

Azacitidine: A Review of its Use in Higher-Risk Myelodysplastic Syndromes/Acute Myeloid Leukaemia

By Keating Gillian M.

Drugs, Vol. 69, Iss. 17, 2009-12 ,pp. : 2501-2518

Adis International

Access to resources Recommend Favorite

NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia

By Breccia Massimo Alimena Giuliana

Expert Opinion on Therapeutic Targets, Vol. 14, Iss. 11, 2010-11 ,pp. : 1157-1176

Informa Healthcare

Access to resources Recommend Favorite